Full Coverage
New Alzheimer's drug aducanumab: cost, side effects, timeline and other questions answered
By Jacqueline Howard
Top news
FDA’s Approval of Biogen’s New Alzheimer’s Drug Has Huge Cost Implications for Medicare and Beneficiaries
By Tricia Neuman & Juliette Cubanski
Third member of FDA expert committee resigns over Alzheimer's decision
By Andrew Joseph
FDA's Approval of Alzheimer's Drug Leads to Third Adviser's Resignation
By Thomas M. Burton
All coverage
Three F.D.A. Advisers Resign Over Agency's Approval of Alzheimer's Drug (Published 2021)
By Pam Belluck & Rebecca Robbins
Third member of prestigious FDA panel resigns over approval of Biogen's Alzheimer's drug
By Berkeley Lovelace & Berkeley Lovelace Jr.
Two members of an FDA advisory committee quit after approval of controversial Alzheimer's drug
By Laurie McGinley
Third member of U.S. FDA advisory panel resigns over Alzheimer's drug approval
By Julie Steenhuysen & Carl O'Donnell